January 29, 2014
The Pharmaceuticals and Medical Devices Agency (PMDA) announced risk information on Bayer Yakuhin’s factor Xa inhibitor rivaroxaban (brand name: Xarelto) and multikinase inhibitor regorafenib (Stivarga) on January 24. The information is currently under review and could result in the revision...read more